Ad hoc: MOLOGEN AG : MOLOGEN AG receives approval for clinical study with cancer drug MGN1703

MOLOGEN AG / Misc. matters / MOLOGEN AG receives approval for
clinical study with cancer drug
MGN1703

Ad hoc announcement according to §15 WpHG processed and transmitted
by Hugin ASA. The issuer is solely responsible for the content of
this announcement.

----------------------------------------------------------------------
--------------

Berlin-based biotechnology company MOLOGEN has received approval from
the relevant health authorities to carry out a study using its
MGN1703 cancer drug, which is based on the dSLIM® DNA
immunomodulator.
The approval-related study (Phase I) will be carried out on cancer
patients to test the safety, compatibility and immunological impact
of MGN1703. Patients who suffer from the most commonly occurring
cancers will be included in the study. It will form the basis of an
extensive clinical development program. MOLOGEN plans to establish
MGN1703 as an effective and compatible form of cancer therapy.
Experts estimate that there is a global market of several billion US
dollars for innovative, immunomodulatory forms of cancer therapy.

The study is to be carried out at the renowned cancer centers of the
university clinics of Essen and Cologne and will last approximately
six months. MOLOGEN believes that the study and patient admission can
commence in a few weeks, as only the last few formalities required by
the authorities still have to be met.

- End of ad hoc announcement -

Explanatory notes for the ad hoc announcement:

"Approval for the MGN1703 study is a great success which rewards our
intensive efforts in this field", said Dr Matthias Schroff, CEO of
MOLOGEN AG. "We now have the chance to demonstrate the great
potential for dSLIM® as an innovative form of cancer therapy."

dSLIM® - an innovative TLR9 agonist
In dSLIM® ("double Stem Loop Immunomodulator"), MOLOGEN has developed
an innovative TLR9 agonist. Use of dSLIM® activates the immune system
to protect against tumor-associated antigens by targeting the TLR9
receptor on certain immune cells. As a result of chemotherapy and
radiotherapy, tumor-associated antigens are released by cancer cells.
The immune system activated by dSLIM® is in a position to overcome
its fatal tolerance towards cancer cells and advance against them
strategically.

Market for immunomodulatory therapies worth billions
In terms of efficacy and compatibility, immunomodulatory therapies
could mean a real medical breakthrough in the fight against cancer.
Experts estimate that there is a global market worth billions of US
Dollars for such therapies.
Pharmaceutical companies are therefore extremely interested in
securing the rights to molecules like TLR9 agonist and testing
substances in many different indications. The recent acquisition of a
US competitor by a globally operating pharmaceutical group is
convincing proof of the great potential attributed internationally to
TLR technology.

About MOLOGEN
MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes
in the research and development of innovative medicines based on DNA
structures (DNA: deoxyribonucleic acid).

Its patented DNA-based platform technologies MIDGE® and dSLIM® form a
universal foundation with a wide range of possible applications.
Activities focus on product developments for the treatment of cancer
and vaccines for serious infections in humans and animals.

MOLOGEN was founded in 1998 and was the first German biotechnology
company to go public. MOLOGEN AG shares are listed in the General
Standard of Deutsche Börse (ISIN DE 0006637200).

Disclaimer concerning prognoses
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future results
of business segments, financial classification numbers, developments
of the financial situation, or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking statements
as certain prognoses of actual future events and developments. The
company is neither responsible nor liable for these forward-looking
statements. It is not responsible for updating such information,
which only represents the state of affairs on the day of publication.

MOLOGEN AG
Fabeckstr. 30, 14195 Berlin, Germany
Contact: Joerg Petrass
Email: investor@mologen.com
Phone: +49-30-84 17 88-13
Fax: +49-30-84 17 88-50

--- End of Message ---

MOLOGEN AG
Fabeckstr. 30 Berlin Germany

WKN: 663720; ISIN:
DE0006637200;
Listed: Freiverkehr in Börse Berlin, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
General Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Stuttgart;